How did Biodesix’s reverse stock split affect the reported insider share numbers?

The footnotes state that the reported share and RSU counts were adjusted to reflect a one-for-twenty reverse stock split that became effective on September 15, 2025 .

Biodesix (NASDAQ: BDSX) CAO reports RSU vesting and tax-driven share sale

Q: What insider activity did Biodesix (BDSX) report for Chris Vazquez?

Biodesix reported that Chief Accounting Officer Chris Vazquez had 219 restricted stock units vest into common shares on January 15, 2026, and that 83 common shares were then sold automatically to cover taxes on January 16, 2026.

Q: How many Biodesix (BDSX) shares did Chris Vazquez sell and at what price?

On January 16, 2026, Chris Vazquez had 83 shares of Biodesix common stock sold automatically to cover taxes at a weighted average price of $8.1493 per share , with individual sale prices ranging from $8.10 to $8.28 .

Q: Were the Biodesix (BDSX) insider sales discretionary or related to taxes?

The Form 4 states that the 83 shares of common stock were sold automatically to cover taxes upon the vesting of RSUs, indicating the sale was tax-related rather than discretionary .

Q: What are the vesting terms of Chris Vazquez’s Biodesix (BDSX) RSUs?

The RSUs reported in the filing vest in four equal annual installments measured from January 15, 2024 , generally subject to Chris Vazquez’s continued service with Biodesix, and they have no expiration date .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Biodesix, Inc. insider Chris Vazquez, the Chief Accounting Officer, reported routine equity transactions involving restricted stock units (RSUs) and related tax sales. On January 15, 2026, 219 RSUs vested and were converted into an equal number of shares of Biodesix common stock at an exercise price of $0, consistent with each RSU representing one share. On January 16, 2026, 83 of these common shares were automatically sold at a weighted average price of $8.1493 per share to cover taxes due upon vesting, with prices ranging from $8.10 to $8.28. Following these transactions, Vazquez directly held 1,072 shares of common stock and 436 RSUs, which vest in four equal annual installments from January 15, 2024. The reported share counts have been adjusted for a one-for-twenty reverse stock split effective September 15, 2025.

Insider Trade Summary

Net Seller: 83 shares ($676)

Net Sell 3 txns

Insider Vazquez Chris

Role Chief Accounting Officer

Sold 83 shs ($676.39)

Type	Security	Shares	Price	Value
Sale	Common Stock	83	$8.1493	$676.39
Exercise	Restricted Stock Units	219	$0.00	--
Exercise	Common Stock	219	$0.00	--

Holdings After Transaction: Common Stock — 1,072 shares (Direct); Restricted Stock Units — 436 shares (Direct)

Footnotes (1)

Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

01/20/2026 - 04:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazquez Chris

(Last)

(First)

(Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE

80027

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/15/2026		M		219	A	⁽¹⁾	1,155	D
Common Stock	01/16/2026		S⁽²⁾		83	D	$8.1493⁽³⁾	1,072	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/15/2026		M			219⁽⁴⁾	⁽⁵⁾	⁽⁵⁾	Common Stock	219⁽⁴⁾	$0	436⁽⁴⁾	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

5. These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Biodesix (BDSX) report for Chris Vazquez?

Biodesix reported that Chief Accounting Officer Chris Vazquez had 219 restricted stock units vest into common shares on January 15, 2026, and that 83 common shares were then sold automatically to cover taxes on January 16, 2026.

How many Biodesix (BDSX) shares did Chris Vazquez sell and at what price?

On January 16, 2026, Chris Vazquez had 83 shares of Biodesix common stock sold automatically to cover taxes at a weighted average price of $8.1493 per share, with individual sale prices ranging from $8.10 to $8.28.

How many Biodesix (BDSX) shares and RSUs does Chris Vazquez hold after these transactions?

After the reported transactions, Chris Vazquez directly beneficially owned 1,072 shares of Biodesix common stock and 436 restricted stock units, as disclosed in the filing.

What are the vesting terms of Chris Vazquez’s Biodesix (BDSX) RSUs?

The RSUs reported in the filing vest in four equal annual installments measured from January 15, 2024, generally subject to Chris Vazquez’s continued service with Biodesix, and they have no expiration date.